
RAPT Stock Forecast & Price Target
RAPT Analyst Ratings
Bulls say
RAPT Therapeutics is positioned for potential growth due to its promising pipeline, particularly related to the RPT904/JYB1904 programs, which may demonstrate differentiated efficacy in clinical trials slated for 2025. The company's RPT904 showcases a commercially validated mechanism of action with enhancements in half-life and pharmacokinetics, representing a de-risked opportunity in immunologic and asthmatic diseases. Additionally, the recent acquisition of Verona Pharma by Merck signals a growing interest within the pharmaceutical industry in immunology and inflammation therapeutics, further supporting RAPT's strategic positioning in the market.
Bears say
RAPT Therapeutics faces significant operational and financial challenges that contribute to a negative outlook for its stock. Key risks include potential safety signals and efficacy issues arising from its clinical programs, which could undermine investor confidence if studies fail to achieve statistical significance. Additionally, the company has considerable financing needs, estimating a cash runway only until 2027, with approximately $1.1 billion required through 2040, raising concerns about its long-term viability amidst increasing competition and regulatory risks.
This aggregate rating is based on analysts' research of Rapt Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPT Analyst Forecast & Price Prediction
Start investing in RAPT
Order type
Buy in
Order amount
Est. shares
0 shares